The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Will ABSORB III change my practice? Everolimus-eluting bioresorbable scaffolds for coronary artery disease

EuroIntervention 2016;12:801-804. DOI: 10.4244/EIJV12I6A130

1. Department of Cardiology, Hospital & University of Fribourg, Fribourg, Switzerland; 2. Department of Cardiology, University of Giessen , Giessen, Germany; 3. Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy; 4.

Introduction to the session

The aim of the article is to capture the session at EuroPCR 2016, communicate the analysis of the trialists, and report the views expressed in the interactive discussion. The article does not constitute an independent review of the topic by the authors. The session focused on whether the ABSORB III trial will change clinical practice1.

Background: what was known before ABSORB III?

A clear overview was presented of the available data before the ABSORB III trial1 in which we were reminded that, at the time the ABSORB III study was in draft, virtually ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Will PARTNER change my practice? Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A trial – transcatheter or surgical aortic-valve replacement in intermediate-risk patients